FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322772023> ?p ?o ?g. }

• W4322772023 endingPage "01" @default.
• W4322772023 startingPage "OT2" @default.
• W4322772023 abstract "Abstract Background: Improving outcomes for patients (pts) with triple-negative breast cancer (TNBC) remains a high unmet need. Immune checkpoint inhibitors (ICIs) + chemotherapy (chemo) and single-agent sacituzumab govitecan, a trophoblast cell-surface antigen 2–targeted antibody-drug conjugate coupled to SN38 via a proprietary, hydrolysable linker, are approved in newly diagnosed pts with programmed death-ligand 1 (PD-L1)–positive tumors and pts who received ≥2 prior systemic therapies (≥1 for metastatic disease), respectively. However, additional options are urgently needed, particularly for pts with tumors that do not express PD-L1 and for those with progression on chemo ± ICI. Magrolimab is an antibody blocking CD47, a “don’t eat me” signal overexpressed on cancer cells, including TNBC, inducing tumor phagocytosis by macrophages. Magrolimab has shown preclinical activity and promising clinical efficacy in hematologic and solid tumors. Chemo agents, including taxanes, can enhance prophagocytic signals on tumor cells, leading to the potential for synergistic antitumor activity with magrolimab. This study is evaluating the safety/tolerability and efficacy of magrolimab in combination with nab-paclitaxel/paclitaxel or with sacituzumab govitecan in unresectable locally advanced/metastatic TNBC. Trial Design: This open-label, 2-cohort (C) study consists of safety run-in and phase (ph)2 portions evaluating nab-paclitaxel/paclitaxel (choice) + magrolimab (safety run-in) or ± magrolimab (ph2, randomized 1:1) in pts with untreated, advanced/metastatic TNBC ineligible for ICI (C1) and magrolimab + sacituzumab govitecan (safety run-in and ph2) in pts with advanced TNBC who received 1 prior systemic treatment in the metastatic setting (C2). Stratification factors for C1 are neoadjuvant and/or adjuvant taxane therapy, liver metastases, and nab-paclitaxel vs paclitaxel. In both cohorts, magrolimab will be administered intravenously (IV) in de-escalating doses to establish the recommended ph2 dose (RP2D). Nab-paclitaxel/paclitaxel and sacituzumab govitecan will be administered IV per standard of care. Eligibility Criteria: Eligible pts are ≥18 y with PD-L1–negative, untreated, unresectable locally advanced/metastatic TNBC (C1) or unresectable locally advanced/metastatic TNBC who received 1 prior line of therapy in the advanced setting, including a taxane and an ICI if PD-L1 positive (C2), with measurable disease per RECIST v1.1. Exclusion criteria include active central nervous system disease, red blood cell transfusion dependence, or prior treatment with CD47/signal regulatory protein α–targeting agents for both cohorts. Additional exclusions are disease progression within 6 months of (neo)adjuvant therapy or rapid visceral progression and/or symptomatic disease, for which single-agent chemo would not be appropriate (C1); chronic inflammatory bowel disease and a history of bowel obstruction or gastrointestinal perforation within 6 months of enrollment, prior treatment with topoisomerase I inhibitors or antibody-drug conjugates containing a topoisomerase inhibitor, and receipt of high-dose systemic corticosteroids within 2 weeks of cycle 1 day 1 (C2). Specific Aims: The primary objectives are safety/tolerability and magrolimab RP2D (safety run-in) and efficacy (ph2: C1, progression-free survival [PFS]; C2, objective response rate [ORR]; both by investigator). Secondary objectives include ORR, PFS, and duration of response by investigator and independent central review, overall survival, and magrolimab concentration vs time and antidrug antibodies. Present and Target Accrual: The study is enrolling in the US, Australia, and Hong Kong. Target accrual is 144 pts. Contact Information: ClinicalTrials.gov: NCT04958785. Citation Format: Natalie Rainey, Rohit Joshi, Joanne Win Yang Chiu, Ann Chen, Hao Wang, Jared Odegard, Michael Howland, Sylvia Adams. A phase 2, randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT2-10-01." @default.
• W4322772023 created "2023-03-03" @default.
• W4322772023 creator A5030183755 @default.
• W4322772023 creator A5035762260 @default.
• W4322772023 creator A5047328930 @default.
• W4322772023 creator A5059063515 @default.
• W4322772023 creator A5059844873 @default.
• W4322772023 creator A5064818110 @default.
• W4322772023 creator A5079207887 @default.
• W4322772023 creator A5080102032 @default.
• W4322772023 date "2023-03-01" @default.
• W4322772023 modified "2023-09-23" @default.
• W4322772023 title "Abstract OT2-10-01: A phase 2, randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer" @default.
• W4322772023 doi "https://doi.org/10.1158/1538-7445.sabcs22-ot2-10-01" @default.
• W4322772023 hasPublicationYear "2023" @default.
• W4322772023 type Work @default.
• W4322772023 citedByCount "0" @default.
• W4322772023 crossrefType "journal-article" @default.
• W4322772023 hasAuthorship W4322772023A5030183755 @default.
• W4322772023 hasAuthorship W4322772023A5035762260 @default.
• W4322772023 hasAuthorship W4322772023A5047328930 @default.
• W4322772023 hasAuthorship W4322772023A5059063515 @default.
• W4322772023 hasAuthorship W4322772023A5059844873 @default.
• W4322772023 hasAuthorship W4322772023A5064818110 @default.
• W4322772023 hasAuthorship W4322772023A5079207887 @default.
• W4322772023 hasAuthorship W4322772023A5080102032 @default.
• W4322772023 hasConcept C121608353 @default.
• W4322772023 hasConcept C126322002 @default.
• W4322772023 hasConcept C143998085 @default.
• W4322772023 hasConcept C197934379 @default.
• W4322772023 hasConcept C2775930923 @default.
• W4322772023 hasConcept C2776694085 @default.
• W4322772023 hasConcept C2777292972 @default.
• W4322772023 hasConcept C2777511904 @default.
• W4322772023 hasConcept C2778375690 @default.
• W4322772023 hasConcept C2779984678 @default.
• W4322772023 hasConcept C2780110267 @default.
• W4322772023 hasConcept C31760486 @default.
• W4322772023 hasConcept C530470458 @default.
• W4322772023 hasConcept C71924100 @default.
• W4322772023 hasConceptScore W4322772023C121608353 @default.
• W4322772023 hasConceptScore W4322772023C126322002 @default.
• W4322772023 hasConceptScore W4322772023C143998085 @default.
• W4322772023 hasConceptScore W4322772023C197934379 @default.
• W4322772023 hasConceptScore W4322772023C2775930923 @default.
• W4322772023 hasConceptScore W4322772023C2776694085 @default.
• W4322772023 hasConceptScore W4322772023C2777292972 @default.
• W4322772023 hasConceptScore W4322772023C2777511904 @default.
• W4322772023 hasConceptScore W4322772023C2778375690 @default.
• W4322772023 hasConceptScore W4322772023C2779984678 @default.
• W4322772023 hasConceptScore W4322772023C2780110267 @default.
• W4322772023 hasConceptScore W4322772023C31760486 @default.
• W4322772023 hasConceptScore W4322772023C530470458 @default.
• W4322772023 hasConceptScore W4322772023C71924100 @default.
• W4322772023 hasIssue "5_Supplement" @default.
• W4322772023 hasLocation W43227720231 @default.
• W4322772023 hasOpenAccess W4322772023 @default.
• W4322772023 hasPrimaryLocation W43227720231 @default.
• W4322772023 hasRelatedWork W2080991642 @default.
• W4322772023 hasRelatedWork W2092771806 @default.
• W4322772023 hasRelatedWork W2261491225 @default.
• W4322772023 hasRelatedWork W2288051007 @default.
• W4322772023 hasRelatedWork W2325706841 @default.
• W4322772023 hasRelatedWork W3132547876 @default.
• W4322772023 hasRelatedWork W3183886430 @default.
• W4322772023 hasRelatedWork W4245186715 @default.
• W4322772023 hasRelatedWork W4250466167 @default.
• W4322772023 hasRelatedWork W4379285952 @default.
• W4322772023 hasVolume "83" @default.
• W4322772023 isParatext "false" @default.
• W4322772023 isRetracted "false" @default.
• W4322772023 workType "article" @default.